<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-59618</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Intravitreal bevacizumab followed by focal laser for diffuse diabetic macular edema of recent progression. A clinical case</dc:title>
<dc:description xml:lang="en">Case report:We report the case of a 48-year-old manwith diffuse diabetic macular edema of recent progressiontreated with two consecutive intravitrealinjections of bevacizumab followed by focal laser therapy,with good anatomic and functional response.Discussion: Diffuse diabetic macular edema is difficultto manage and frequently requires multipletherapies. We propose the use of bevacizumab as astrategy to reduce diffuse macular edema, facilitatingthe application of laser therapy(AU)</dc:description>
<dc:creator>Moreno-López, M</dc:creator>
<dc:creator>Regueras, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Caso clínico: Se presenta el caso de un varón de 48años de edad con edema macular diabético (EMD)difuso en su ojo derecho (OD) de reciente progresión,que es tratado con dos inyecciones intravítreasconsecutivas de bevacizumab seguido de láserfocal, mostrando buena respuesta funcional y anatómica.Discusión: El EMD difuso es de difícil manejo ycon frecuencia precisa de multiterapias para su control.Proponemos el uso de bevacizumab intravítreocomo coadyuvante para reducir el EMD difuso deprogresión reciente, y facilitar la aplicación de fotocoagulacióncon láser(AU)</dc:description>
<dc:source>Arch Soc Esp Oftalmol;84(4): 209-212, abr. 2009. ilus</dc:source>
<dc:identifier>ibc-59618</dc:identifier>
<dc:title xml:lang="es">Bevacizumab intravítreo seguido de láser focal en el edema macular diabético difuso de progresión reciente. Caso clínico</dc:title>
<dc:subject>^d3954^s22012</dc:subject>
<dc:subject>^d3954^s22057</dc:subject>
<dc:subject>^d22656^s22012</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d8204^s22045</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d9041^s22074</dc:subject>
<dc:subject>^d23247^s22074</dc:subject>
<dc:subject>^d34460^s22073</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d24366^s22031</dc:subject>
<dc:subject>^d28131^s22057</dc:subject>
<dc:subject>^d24366^s22021</dc:subject>
<dc:subject>^d28131^s22016</dc:subject>
<dc:subject>^d28131^s22059</dc:subject>
<dc:subject>^d38644^s22016</dc:subject>
<dc:type>article</dc:type>
<dc:date>200904</dc:date>
</metadata>
</record>
</ibecs-document>
